Bluejay Diagnostics, Inc. (NASDAQ: BJDX) has filed a 424B3 prospectus supplement registering 11,223,665 shares for resale — approximately 10.8 times the company's current 1,034,715 shares outstanding. The registered shares are derived entirely from warrants issued in a recent private placement.
What the filing covers
The resale registration encompasses shares underlying warrants from a June 2026 private placement. Among the warrants are 3,655,917 pre-funded warrants carrying an exercise price of $0.0001 per share. At that price, exercise is essentially costless to the holder, meaning these warrants function as deferred share issuance rather than a meaningful capital raise for the company. The remaining warrants account for the balance of the 11.2 million registered shares.
Because pre-funded warrants at a nominal strike price carry no practical barrier to exercise, they can convert to common shares at any time without regard to market price. There is no disclosed floor price or minimum threshold that would limit conversion.
Structural significance
The ratio of registered shares to outstanding shares is the critical metric here. When a resale shelf covers more than ten times the existing float, full conversion would restructure the capitalization almost entirely in favor of the new warrant holders. Existing shareholders' proportional ownership would decline substantially.
The filing also permits cashless exercise of certain warrants, which means holders may convert without injecting additional cash, further reducing any potential capital inflow to the company.
Reverse-split history
Bluejay Diagnostics has executed cumulative reverse stock splits totaling a 1-for-32,000 ratio since July 2023. Reverse splits consolidate outstanding shares to maintain exchange listing compliance but do not alter market capitalization on their own. In this case, the successive consolidations have compressed the outstanding share count to just over one million shares — the base against which the 11.2 million newly registered shares now sit.
The company's stock has declined more than 99.9% from its IPO price, reflecting the cumulative dilution and reverse-split cycle.
Dilution mechanics in context
When pre-funded warrants carry a near-zero exercise price and no floor provision governs conversion, the dilution pathway is mechanically straightforward: holders can convert at will, and each conversion adds shares to the public float without a corresponding market-price transaction. The 424B3 registration clears the warrants' underlying shares for immediate resale upon exercise, removing any restrictive-legend friction.
The filing's red-flag profile — nominal-strike pre-funded warrants, cashless exercise provisions, deep-discount issuance, and the absence of a price floor — concentrates dilution risk at the structural level rather than distributing it across contingencies that may or may not trigger.